Marsi-Bionics has raised 943,000 euros through the Fellow Funders Equity Crowdfunding platform, achieving 118% of the €800,000 target in a funding round attended by 154 investors.
These funds will help the company tackle the commercialization process in public hospitals of Atlas 2030: the world’s first robotic and articulated pediatric exoskeleton. The funding round closed a month after the Agencia Española del Medicamento y Productos Sanitarios “Aemps” (Spanish Agency of Medicines and Health Products) granted the CE quality seal to this development.
The project, led by Elena García, is entire of Spanish origin and uses patented technology, unique in the market, developed by the team of the Centro de Automática y Robótica (CAR), a joint center of the Universidad Politécnica de Madrid (UPM) and the Consejo Superior de Investigaciones Científicas (CSIC).
Marsi-Bionics boasts another exoskeleton already on the market: the Marsi Active Knee (MAK), a portable robotic knee designed for record-time, pain-free rehabilitation of joint surgeries, including knee prostheses and movement complications in stroke victims.
Over the past five years, the company has managed to increase its revenues from €350,000 in 2016 to over €1 million in 2019.
The company plans to reach a new turning point in 2022 by launching Stelo, its exoskeleton for adults, expecting to quadruple its revenue to €10 million.
“The success of the Marsi-Bionics funding round confirms our commitment to ESG investments in the Junior market, providing social benefits and profitability for our investors. We have an important ‘track record’ in the MedTech sector,” said the Fellow Funders Crowdfunding Investment division director, Ernesto Muñoz.
Source: Europa Press
Media that have echoed the news: Bolsamanía, El Confidencial Digital, Negocios, Diario Siglo XXI, Pressdigital, Norbolsa, Cantabria Económica, Crónica de Cantabria.